Alluvi, previously BI 4744, offers a promising development in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling effectiveness https://socialwebleads.com/story7680412/alluvi-a-comprehensive-examination-into-retatrutide-s-possibilities